Ixchelsis retains Bonaccord as corporate legal counsel (www.bonaccord.eu), November 2011.
Ixchelsis retains Bonaccord as corporate legal counsel, November 2011.
November 27, 2011 by
Innovators in Reproductive Health
Latest News
May 2017: Members of the Ixchelsis Scientific Advisory Board Present Clinical Results for a Study of IX-01 in Men with PE at American Urological Association Meeting. Boston May 12th -16th 2017
Ixchelsis is pleased to announce that two abstracts relating to the results of the proof of concept trial (PEPIX) of IX-01 in men with lifelong premature ejaculation were accepted … [Read More...]
May 2017: Ixchelsis CEO Gary Muirhead Attended BioTrinity May 08th -10th 2017
Ixchelsis CEO, Gary Muirhead attended BioTrinity in London, May 08-10 2017. Please contact us through the website for further information. … [Read More...]
February 2017: Ixchelsis Announces Start of Phase II B Dose Range-Finding Study for IX-01
Following the positive proof-of-concept data released in 2016, Ixchelsis is pleased to announce the start of the Phase II B dose range-finding study for IX-01 in February 2017. The … [Read More...]